ANI Pharmaceuticals Acquires Four ANDAs from Oakrum Pharma, LLC

ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M

March 9, 2021

Pharmaceuticals

ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.

Ampersand Capital Partners Acquires Purna Pharmaceuticals

February 12, 2026

Pharmaceuticals

Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.

ANI Pharmaceuticals Fights Alimera Sciences Lawsuit to Compel Closing of Merger

September 10, 2024

Pharmaceuticals

Alimera Sciences filed a lawsuit in Delaware Court of Chancery seeking to compel ANI Pharmaceuticals to close their previously announced merger under the June 21, 2024 Agreement and Plan of Merger. Alimera says it satisfied its own closing requirements and that its shareholders approved the transaction on September 4, 2024, while ANI allegedly failed to close on time.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

ANJAC Health & Beauty Acquires Pillar5 Pharma

March 14, 2022

Pharmaceuticals

French family-owned ANJAC Health & Beauty has acquired Pillar5 Pharma, a Canadian CDMO specializing in sterile ophthalmic solutions and niche solid-dose manufacturing. The deal strengthens ANJAC's presence in North America and expands its pharmaceutical and ophthalmology capabilities; Pillar5 is based in Arnprior, Ontario and has roughly 150 employees and CAD$50M in revenue.

Eli Lilly Acquires Orna Therapeutics in Up to $2.4 Billion Deal

February 9, 2026

Biotechnology

Eli Lilly and Company has signed a definitive agreement to acquire Orna Therapeutics, valuing the deal at up to $2.4 billion. The acquisition is intended to expand Lilly’s genetic medicine and in vivo cell engineering capabilities, particularly for advancing in vivo CAR-T therapies using Orna’s circular RNA and lipid nanoparticle (LNP) platform.